Should I buy Eli Lilly and Company (LLY)?

What Strong Buy means for LLY today

A Strong Buy rating is the output of the composite fair-value band ($1025–$1936) compared with the live price ($975), a 9/10 moat score, and a 88/100 confidence reading on the data quality and model convergence behind the fair-value range. We do not issue Buy / Strong Buy unless valuation is in the strong half of our six-factor decision overlay AND the risk profile is non-elevated; the rating is gated, not free-form.

LLY is rated Strong Buy at $974.96 versus the reconciled fair value midpoint of $1,465.75, implying +50.34% upside/downside. Confidence is separately disclosed at 88/100. The full report explains every input: discount rate, terminal growth, deceleration curve, scenario probabilities, and where the rating could change next.

Bull, base and bear over our base horizon

Bull case (probability 25%): target $1,935.83, return +98.6%. Base case (probability 50%): target $1,465.75, return +50.3%. Bear case (probability 25%): target $1,025.31, return +5.2%.

Probability weights are not symmetric. Eli Lilly and Company is a hyper-growth stock, so the deceleration curve, terminal P/E, and confidence in the bull tail are calibrated to that archetype. The probability-weighted expected value in the full report folds these three scenarios into a single asymmetric expected return — a more honest "should I buy?" signal than any single point estimate.

Risks to the thesis

The top kill-scenarios our latest report flags for Eli Lilly and Company are: Severe Pricing Regulation; Long-Term Safety Signal; Oral Competitor Domination. The single biggest risk is Severe Pricing Regulation: Medicare aggressively negotiates GLP-1 pricing, capping margins and triggering cascading price cuts across commercial channels.

The biggest opportunity is The $1,465.75 fair value bridges the benchmark gap by correctly weighting forward EPS to capture explicit pipeline momentum. Position management in the full report converts the rating into concrete checkpoints — quarterly reassessment triggers and the metric thresholds that should change the size of the position rather than the position itself.

Bottom line

Our Strong Buy rating with 88/100 confidence is research for educational purposes — not personalised investment advice and not a price call. Use the fair-value range and the bull/base/bear distribution to size a view; use the kill-scenarios and the earnings decision tree to define what would invalidate it.

For the full evidence — 14 sections, sensitivity grid, scorecard, and the data-provenance appendix — see the canonical report at /stocks/lly/analysis.

Frequently asked questions